Inventor
Melanie K. Spriggs
Inventor
Seattle, WA, US
Overview
Patents· 33 as inventor
Public. Assignee & technology derived from the patent record. Each patent links to its LexDana page.
A61Kprimary
A61KPreparations for medical, dental or toiletry purposes32%
C07KPeptides32%
C12NMicroorganisms or enzymes23%
A61PSpecific therapeutic activity of chemical compounds or medicinal preparations7%
A01KAnimal husbandry3%
C12QMeasuring or testing processes involving enzymes, nucleic acids or microorganisms3%
Y10STechnical subjects covered by former uspc cross-reference art collections [xracs] and digests1%
PatentTitleYear
7,432,237'Methods of treating asthma by administering interleukin-17 receptor'20087,405,270'CD40-Ligand lacking native-pattern glycosylation'20087,309,489'Mouse CD40 ligand-specific antibodies and hybridomas'20077,273,843'Methods of treating allergy by administering interleukin-17 receptor'20077,214,497'Viral encoded semaphorin protein receptor DNA and polypeptides'20076,680,057'Methods of treating autoimmune disease by administering interleukin-17 receptor'20046,670,135'Semaphorin polypeptides'20036,613,320'Defective CD4T-cells that express active CD40-L'20036,562,949'Antibodies to viral encoded semaphorin protein receptor polypeptides'20036,410,711'DNA encoding CD40 ligand, a cytokine that binds CD40'20026,391,637'Use of CD40 ligand, a cytokine that binds CD40, to stimulate hybridoma cells'20026,290,972'Method of augmenting a vaccine response by administering CD40 ligand'20016,264,951'Methods of inhibiting CD40L binding to CD40 with soluble monomeric CD40L'20016,197,525'Assay kits for detection and methods of inhibiting IL-17 binding'20016,191,104'Methods of treating graft rejection with the IL-17 receptor'20016,187,909'Viral encoded semaphorin protein receptor polypeptides'20016,174,689'Viral encoded semaphorin protein receptor DNA and polypeptides'20016,130,068'Viral encoded semaphorin protein receptor DNA and polypeptides'20006,106,832'Treatment of individuals exhibiting defective CD40L'20006,100,235'Methods of treating immune and inflammatory response with IL-17 receptors'20006,096,305'Receptor that binds IL-17'20006,087,329'CD40 ligand polypeptide'20006,072,033'Receptor that binds IL-17'20006,072,037'Antibodies to the IL-17 receptor'20005,981,724'DNA encoding CD40 ligand, a cytokine that binds CD40'19995,961,974'Monoclonal antibodies to CD40 ligand, pharmaceutical composition comprising the same and hybridomas producing the same'19995,962,406'Recombinant soluble CD40 ligand polypeptide and pharmaceutical composition containing the same'19995,925,734'Isolated Epstein-Barr virus BZLF2 proteins that bind MHC class II .beta.chains'19995,869,286'Receptor that binds IL-17'19995,726,286'Isolated epstein-barr virus BZLF2 proteins that bind MHC class II beta chains'19985,716,623'Isolated Herpesvirus saimiri proteins that bind MHC Class II molecules'19985,716,805'Methods of preparing soluble, oligomeric proteins'19985,565,321'Detection of mutations in a CD40 ligand gene'1996Career & activity timeline
Assembled from patent assignee/location history and declaration credentials.
1996–2008Patents assigned to IMMUNEX CORP (32)· patent assignee history
1996–2008Based in Seattle, WA, US· patent location history
Inventor activity
Assignee and location history derived from the patent record.
Assignees
| Assignee | Patents | Span |
|---|---|---|
| IMMUNEX CORP | 32 | 1996–2008 |
Locations
| Location | Patents | Span |
|---|---|---|
| Seattle, Washington, US | 33 | 1996–2008 |